MARKET

APRE

APRE

Aprea Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.850
-0.210
-4.15%
After Hours: 5.50 +0.65 +13.40% 18:50 09/20 EDT
OPEN
5.47
PREV CLOSE
5.06
HIGH
5.59
LOW
4.730
VOLUME
16.76M
TURNOVER
--
52 WEEK HIGH
30.99
52 WEEK LOW
3.170
MARKET CAP
102.76M
P/E (TTM)
-2.1574
1D
5D
1M
3M
1Y
5Y
Aprea Therapeutics Presents Data From Phase 1/2 Trial Of Eprenetapopt In Advanced Solid Tumors At ESMO Congress 2021
Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today presented data
Benzinga · 2h ago
Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021
BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today presented da...
GlobeNewswire · 2h ago
Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock?
Zacks.com · 10h ago
SDC, EDSA and APRE among pre market gainers
ZIVO Bioscience (NASDAQ:ZIVO) +175%. Verastem (NASDAQ:VSTM) +22% Oncology's VS-6766 + defactinib combo shows promising action in ovarian cancer study Edesa Biotech (NASDAQ:EDSA) +33% announces positive phase 2 data of its monoclonal antibody in
Seekingalpha · 10h ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 10h ago
24 Stocks Moving in Monday's Pre-Market Session
Gainers Verastem, Inc. (NASDAQ: VSTM) rose 30.8% to $3.61 in pre-market trading after the company announced a mini oral presentation highlighting updated data from the ongoing investigator-sponsored Phase 1/2 FRAME study.
Benzinga · 11h ago
Top Premarket Gainers
MT Newswires · 14h ago
Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced an upcoming presentation of data for epreneta...
GlobeNewswire · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APRE. Analyze the recent business situations of Aprea Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APRE stock price target is 4.000 with a high estimate of 5.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 65
Institutional Holdings: 6.56M
% Owned: 30.96%
Shares Outstanding: 21.19M
TypeInstitutionsShares
Increased
9
459.57K
New
9
339.85K
Decreased
21
1.13M
Sold Out
26
2.07M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chairman/President/Chief Executive Officer/Director
Christian Schade
Chief Financial Officer/Senior Vice President/Secretary
Scott Coiante
Senior Vice President/Chief Scientific Officer
Lars Abrahmsen
Senior Vice President
Eyal Attar
Senior Vice President
Gregory Korbel
Lead Director/Independent Director
John Henneman
Independent Director
Johan Christenson
Independent Director
Michael Kelly
Independent Director
Fouad Namouni
Independent Director
Richard Peters
Independent Director
Bernd Seizinger
No Data
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate, APR-246, is a small molecule p53 reactivator that is being developed for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator. APR-548 is being developed in an oral dosage form.

Webull offers kinds of Aprea Therapeutics Inc stock information, including NASDAQ:APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.